Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 9241896 | 8 pages | https://doi.org/10.1155/2019/9241896

Xiaokeping Mixture Attenuates Diabetic Kidney Disease by Modulating TGF-β/Smad Pathway in db/db Mice

Academic Editor: Mario Ledda
Received12 May 2019
Accepted06 Sep 2019
Published08 Oct 2019


Xiaokeping mixture (XKP), a traditional Chinese medicine compound preparation, has achieved widespread use for diabetes mellitus and its kidney damage in clinical practice. The current study was carried out to assess the protective effect of XKP in spontaneous diabetic db/db mice and the underlying mechanism whereby XKP regulates TGF-β/Smad pathway. Male C57BLKS/J db/db mice, 12 weeks old, were randomly divided into 3 groups: the model group, 17.5 mg/kg irbesartan-treated group (IST group), and 8 g/kg XKP-treated group (XKP group), while age-matched db/m mice were selected as a control group. After 8 weeks of administration, serum and urea samples were collected from mice for biochemical tests, while the kidneys were removed for histological analysis. The expression of TGF-β/Smad pathway-related mRNA and protein were measured by RT-PCR and western blot analysis. Treatment with XKP significantly improved renal function and attenuated the pathological change of diabetic kidney disease (DKD) in renal histopathology. Furthermore, the overexpression of TGF-β1, Smad3, and p-Smad3 was inhibited, as well as the reduction of Smad7 and SIP1 was weakened by XKP. In conclusion, these results suggest that XKP could attenuate DKD by modulating TGF-β/Smad pathway.

1. Introduction

Diabetic kidney disease (DKD) is one of the most prevalent and severe chronic microvascular complications of diabetes mellitus that eventually leads to end-stage renal failure [1]. A major pathological change in DKD is characterized by abnormal metabolism of extracellular matrix components (ECM) [2]. As a critical cell regulatory factor, TGF-β plays a key role in the synthesis and accumulation of ECM in mesangial cells [3]. When various damage factors (such as high glucose levels) appear, TGF-β1 appears to be overexpressed, induces changes in mesangial cell function and morphology, and promotes increased secretion of ECM [4]. Further, blocking the activity of TGF-β1 contributes to attenuate DKD.

TGF-β1 binds to two transmembrane receptors, type I (TGF-βR1) and type II (TGF-βRII), forming a heterotetramer that leads to phosphorylation of Smad2 and Smad3. Then associated with Smad4, heteroligomerize is formed and translocates into the nucleus where it is involved in the transcription of TGF-β-responsive genes [5, 6]. Additionally, Smad7 is a negative regulator that could rapidly regulate the feedback mechanism of TGF-β response by competitively binding to TGF-βR1 and disrupting heteroligomerize [7].

Xiaokeping mixture (XKP), comprising Radix Astragali (Astragalus membranaceus (Fisch.) Bge), Rhizoma Dioscoreae (Dioscorea oppositifolia L.), Radix Rehmanniae Preparata (Rehmannia glutinosa (Gaert.) Libosch. ex Fisch. et Mey.), Radix Ophiopogonis (Ophiopogon japonicus (Linn. f.) Ker-Gawl.), Radix trichosanthis (Trichosanthes kirilowii Maxim.), Radix Salvia MiltiorrHizae (Salvia miltiorrhiza Bunge), Flos Chrysanthemi (Dendranthema morifolium (Ramat.) Tzvel.), and Fructus LyCii (Lycium barbarum L.), has achieved widespread use for diabetes mellitus and its kidney damage in clinical practice for decades [8,9]. Recent studies have demonstrated that XKP can effectively attenuate DKD in a rat model by inhibiting the expression of VEGF and ETS-1 [10]. XKP showed pancreatic β-cells protection against apoptosis under high glucose stress through mTOR-mediated autophagy pathway [11]. By restraining the activation of miR-192, XKP could be used to treat DKD induced by STZ [12]. Astragaloside A, one of the main active ingredients of XKP, has an antioxidation and hepatoprotection effect through downregulating the TGF-β/Smad signaling pathway [13]. Some herbs in XKP, such as Radix Astragali, Salvia MiltiorrHizae, and Fructus LyCii, can modulate the expression of TGF-β in animal experiment [1416].

Hence, it is essential to understand the underlying mechanisms of XKP in the treatment of DKD. In this study, we employed spontaneous diabetic db/db mice to investigate the effects of XKP on the TGF-β/Smad pathway.

2. Materials and Methods

2.1. Reagents

Xiaokeping mixture was obtained from Tongde Hospital of Zhejiang Province (Hangzhou, China).

2.2. Experimental Animals and Treatment

All experiments were performed in accordance with the guidelines on ethical standards for investigations in animals, and the study was approved by the Tongde Hospital of Zhejiang Province animal research committee (No. XMSC2017024). 11-week-old male C57BLKS/J db/db and their age-matched db/m mice weighing 42.7 ± 2.8 g were purchased from Shanghai Slaccas Inc. (Shanghai, China). All mice were housed in a climate-controlled room at 24°C and 50% humidity under a 12 h light/dark cycle and had free access to water in the Animal Center of Zhejiang Chinese Medical University. At 12 weeks of age, the db/db mice were randomly divided into three groups ( for each group) and orally administered, respectively, with saline (model group), 17.5 mg/kg irbesartan (IST group), and 8 g/kg XKP (XKP group). 12 male db/m mice, as control, were treated with an equivalent volume of saline. At 20 weeks of age, blood samples were drawn from aortaventralis, and urine samples were collected for biochemical detection. Mice were sacrificed by cervical dislocation, and kidneys were removed for histological, polymerase chain reaction (PCR) and western blotting assays.

2.3. Blood Biochemical Analysis

Blood glucose level, blood urea nitrogen, and serum creatinine were measured by an Automated Biochemical Analyzer (Hitachi, Japan).

2.4. Urine Analysis

In the end of experiment, mice were transferred to the metabolic cages for 24 h where urine samples were collected. Urine creatinine and albumin concentrations were determined by an Automated Biochemical Analyzer (Hitachi, Japan).

2.5. Renal Histological Analysis

Kidney sections were fixed in 4% buffered paraformaldehyde, embedded in paraffin, and cut into 4 μm thick sections which were prepared for HE staining. Ten glomeruli for each mice were evaluated in a blinded analysis in kidney sections. The degree of glomerulus damage was assessed by a semiquantitative method as follows: no damage (grade 0, normal glomeruli); minimal damage (grade 1, mesangial expansion area up to 25%); moderate damage (grade 2, 26–50% expansion); moderate-to-severe damage (grade 3, 51–75% expansion); and severe damage (grade 4, 76–100% expansion). The glomerular matrix index (GMI) was then calculated by the following formula:

2.6. Analysis of TGF-β1, Smad3, Smad7, and SIP1 mRNA Expressions by Reverse Transcriptase-PCR

Total RNA was extracted from kidney tissues using the Trizol reagent (Sangon Biotech, Shanghai, China) as described in the instruction. Reverse transcribed to cDNA was conducted following the instruction of reverse transcription kit (ComWin Biotech, Beijing, China). The primer sequences, designed and synthesized by ComWin Biotech Co., Ltd (Beijing, China), are listed in Table 1. The conditions of PCR cycling were as follows: predenaturation at 95°C for 10 min, 40 cycles at 95°C for 15 s, and 60°C for s60. The relative expression level of target gene was determined by method. Following RT-PCR, melting curve analysis was performed immediately for homogenization.

NameUpstream primer (5′–3′)Downstream primer (5′–3′)


2.7. Western Blot Analysis for TGF-β1, Smad3/7, p-Smad3, and SIP1

Renal tissues were homogenized in radioimmunoprecipitation assay (RIPA) lysis buffer (200 mg tumor tissue/1 ml RIPA, Beyotime Biotechnology, Shanghai, China) for 30 min on ice, and then centrifuged at 12,000 rpm for 5 min, supernatants were collected. The protein concentration was determined by the bicinchoninic acid (BCA) protein assay (Solarbio, Beijing, China). Protein samples were separated by electrophoresis on 5% SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF) membranes. Blocked in 5% (W/V) nonfat milk for 1.5 h, the membranes were incubated with the primary antibody against TGF-β1 (Abcam, Cambridge, UK), Smad3 (Affinity Biosciences, Ohio, USA), Smad7 (Affinity Biosciences, Ohio, USA), SIP1 (Abcam, Cambridge, UK), p-Smad3 (Cell Signaling Technology, Massachusetts, USA), and GAPDH (Proteintech, Illinois, USA) at 4°C overnight. After washing three times in TBST, the membrane was treated with horseradish peroxidase (HRP)-linked secondary antibody (Cell Signaling Technology, Massachusetts, USA) for 1 h and then washed three times in TBST. Density of the corresponding bands was measured by using chemiluminescence detection reagents (Solarbio, Beijing, China) and analyzed with Quantity One software.

2.8. Statistical Analysis

Data analysis was performed using SPSS 19.0, and the data are expressed as means ± SD. The LSD method in one-way ANOVA was used to compare the two groups in different groups, and was considered as significant.

3. Result

3.1. Effects of Xiaokeping Mixture on Biochemical Indicators

There is no accidental death of mice occurred throughout the experiment. After 8 weeks of administration, there is a significant difference in blood glucose levels, blood urea nitrogen, serum creatinine, urine creatinine, and urine albumin between the control group and the model group (Figure 1). Furthermore, treatment with XKP significantly reduced the blood glucose levels , blood urea nitrogen , serum creatinine , and urine albumin in db/db mice, while urine creatinine was significantly increased (Figure 1).

3.2. Effects of Xiaokeping Mixture on Renal Pathology

As shown in Figure 2(A), the kidney tissue of the control group was intact and clear, the basement membrane was smooth, and no obvious pathological changes were found in the glomeruli. By contrast, many necrosis symptoms of DKD-induced kidney tissue have been observed in the model group such as basement membrane thickening, increased mesangial matrix, and mesangial cell proliferation (Figure 2(B)). XKP treatment attenuated the above symptoms (Figure 2(D)). The GMI score was significantly lower in the XKP group than in the model group.

3.3. Effects of Xiaokeping Mixture on the Expression of TGF-β1, Smad3, Smad7, and SIP1 at the mRNA Level

In order to evaluate the underlying mechanism of XKP in improving DKD, we measured the expression of TGF-β/Smad pathway-related mRNA by quantitative real-time PCR. The mRNA expression of TGF-β1 and Smad3 were significantly increased while the expression of Smad7 and SIP1 were significantly decreased in the model group compared to relative levels in the control group (Figure 3). However, treatment with XKP markedly attenuated these trends (Figure 3).

3.4. Effects of Xiaokeping Mixture on the Expression of TGF-β1, Smad3/7, p-Smad3, and SIP1 at the Protein Level

Western blot analysis was also used to verify the impact of XKP on DKD. Mice in the model exhibited significantly increased protein expression of TGF-β1 and Smad3 , as well as markedly decreased protein expression of Smad7 and SIP1 compared with the control group. Just as the effects on mRNA expression, XKP also dramatically attenuates these deteriorating trends (Figure 4). Phosphorylation activation of Smad3 is one of the important markers of Smad signaling pathway activation. Thus, a balance between p-Smad3 and Smad3 reflects the progression of DKD. The expression of p-Smad3 was also examined, and its ratio to Smad3 showed a significant increase in the model group when compared with the control group. Similarly, XKP significantly inhibits phosphorylation of Smad3 (Figure 4).

4. Discussion

Diabetes kidney disease, one of the major microvascular complications of diabetes, is closely related to microvascular inflammatory response caused by long-term hyperglycemia [17]. This study suggests that treatment with XKP regulates the expression of TGF-β/Smad pathway-related mRNA and protein, thereby delaying DKD progression.

The db/db mouse, a spontaneous model of type 2 diabetes, carries a G-to-T point mutation of the leptin receptor on chromosome 4 that leads to hyperphagia, decreased energy expenditure, hyperglycemia, and insulin resistance [18]. Compared with the traditional STZ-induced DKD model, the db/db mouse model of type 2 diabetes is more stable and can reduce individual differences, which is considered to be an ideal animal model of diabetes [19, 20]. In general, the db/db mice develop abnormal glucose tolerance at 3-4 weeks of age, proteinuria at 7-8 weeks of age, obvious symptoms of diabetic nephropathy at 12 weeks of age, and renal histopathological features resembling those of human diabetic nephropathy [21]. Moreover, mesangial matrix diffuse increase, and glomerular tuberous sclerosis had been found in the HE staining of model mice, which was consistent with previous reports [22].

Many Chinese herbal medicines are considered to have anti-inflammatory effects and widely used in the treatment of chronic inflammatory diseases such as diabetes. According to traditional Chinese medicine theory, Radix Astragali, Rhizoma Dioscoreae, Radix Rehmanniae Preparata, Radix Ophiopogonis, Radix trichosanthis, Radix Salvia MiltiorrHizae, Flos Chrysanthemi, and Fructus LyCii are made into compound preparation for the treatment of diabetic kidney disease. Referring to the name of diabetes in traditional Chinese medicine theory, the compound preparation is named as xiaokeping mixture. The major constituents of xiaokeping mixture have been shown to regulate blood sugar levels and prevent complications of diabetes in animal experiments and clinical observation. Since Radix Astragali and Rhizoma Dioscoreae are one of the main components of XKP, they have a significant effect on lowering blood sugar [23]. As a result of lowering blood sugar, the glucose toxicity of db/db mice is alleviated, and diabetic kidney disease is relieved to some extent. In addition, some herbal medicine with the function of promoting blood circulation and removing blood stasis and collaterals is the basic treatment for diabetic kidney disease based on the theory of traditional Chinese medicine. And the two components of XKP, Radix Salvia MiltiorrHizae and Radix Rehmanniae Preparata have been confirmed to have the function of promoting blood circulation and removing blood stasis and collaterals in previous studies [24]. However, the renoprotective mechanism of XKP for diabetic kidney disease has not yet been fully defined. In the current study, XKP was demonstrated to have hypoglycemic effects while attenuating the progression of DKD. Blood urea nitrogen, serum creatinine, urine creatinine, and albumin in 24-hour urine are considered indicators for evaluating renal function. Renal deterioration usually manifests as elevated blood urea nitrogen, elevated serum creatinine, decreased urine creatinine, and albuminuria, which were observed in db/db mice. However, treatment with XKP reversed the above symptoms and improved the renal function. Pathological evidence further supports this result.

TGF-β is a cytokine that regulates cell growth and differentiation, including three isoforms β1, β2, and β3 [25]. Furthermore, the distribution of the TGF family in the kidney is dominated by TGF-β1, which regulates multiple pathways to influence the progression of renal fibrosis. As an important intracellular kinase substrate, Smad family proteins play a key role in the transmission of TGF-β signaling from cell surface receptors to the nucleus [3]. Therefore, we aimed to investigate the mechanism of XKP attenuating DKD by focusing on the TGF-β/Smad pathway. In the TGF-β/Smad pathway, Smad2 and Smad3 were known to accelerate renal fibrosis, whereas Smad 7 can inhibit TGF-β signal transduction to prevent fibrosis. In the current study, XKP can reduce the expression of TGF-β1 and Smad3 in the db/db mice and upregulate the expression of Smad7. Additionally, the regulation of TGF-β1 was inseparable from the activation and phosphorylation of Smad3. XKP also reduced the expression of p-Smad3, which provides further evidence for the effectiveness of XKP in the treatment of DKD.

SIP1, an abbreviation for Smad-interacting protein 1, was thought to play a role in the TGF-β signaling pathway. SIP1 could bind tightly to Smad 1, 2, 3, 5, and 8 via the Smad-interacting domain for SMAD interaction that acts as a cotranscriptional repressor [26]. SIP1 is also a member of the δ-EF1 family of two-handed zinc-finger factors (Zeb2), which have been described to directly repress transcription of target genes by binding to the E2 boxes (CACCTG sequence) in their promoter [27]. In the process of renal fibrosis, ECM and epithelial-to-mesenchymal transition (EMT) are very important pathological changes. These changes involve many cytokines such as E-cadherin, vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), plasminogen activator inhibitor 1 (PAI-1), and matrix metalloproteinases (MMPs) [28, 29]. Interestingly, cytokines mentioned above are regulated by SIP1 [27, 3033]. Obviously, these regulations are complicated and networked. Differential fine tuning of SIP1 in interstitial fibrosis may result in controversial functional consequences [34, 35]. In the current study, when compared with the control group, a marked downregulation of SIP1 expression in the kidney tissue of db/db mice was observed, which was consistent with previous studies [36]. Notably, treatment with XKP promoted the expression of SIP1, which was associated with improved renal function.

5. Conclusions

In conclusion, we demonstrated the protective role of XKP in type 2 diabetic db/db mice. XKP could effectively regulate blood sugar levels and attenuate DKD, which is likely related to inhibition of TGF-β/Smad pathway.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no competing interest.


This study was supported by the National Natural Science Foundation of China (no. 81774270), the New Medical Talent Training Plan of Zhejiang Province in 2017, 111 Talent Training Plan in Tongde Hospital of Zhejiang Province, and research fund of Zhejiang Province Association of Chinese Integrative Medicine (no. 2016LYK015).


  1. S. M. Doshi and A. N. Friedman, “Diagnosis and management of type 2 diabetic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 12, no. 8, pp. 1366–1373, 2017. View at: Publisher Site | Google Scholar
  2. R. Z. Alicic, M. T. Rooney, and K. R. Tuttle, “Diabetic kidney disease: challenges, progress, and possibilities,” Clinical Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2032–2045, 2017. View at: Publisher Site | Google Scholar
  3. X.-M. Meng, D. J. Nikolic-Paterson, and H. Y. Lan, “TGF-β: the master regulator of fibrosis,” Nature Reviews Nephrology, vol. 12, no. 6, pp. 325–338, 2016. View at: Publisher Site | Google Scholar
  4. Y. Nie, S. Li, Y. Yi et al., “Effects of astragalus injection on the TGFβ/Smad pathway in the kidney in type 2 diabetic mice,” BMC Complementary and Alternative Medicine, vol. 14, no. 1, 2014. View at: Publisher Site | Google Scholar
  5. J.-Y. Kim, H.-J. An, W.-H. Kim et al., “Anti-fibrotic effects of synthetic oligodeoxynucleotide for TGF-β1 and Smad in an animal model of liver cirrhosis,” Molecular Therapy–Nucleic Acids, vol. 8, pp. 250–263, 2017. View at: Publisher Site | Google Scholar
  6. H. S. Chen, Y. Q. Xu, Y. X. Yang, X. J. Zhou, S. J. Dai, and C. Li, “Shenqiwan ameliorates renal fibrosis in rats by inhibiting TGF-β1/Smads Signaling pathway,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 7187038, 9 pages, 2017. View at: Publisher Site | Google Scholar
  7. Y. Tian, F. Liao, G. Wu et al., “Ubiquitination and regulation of Smad7 in the TGF-β1/Smad signaling of aristolochic acid nephropathy,” Toxicology Mechanisms and Methods, vol. 25, no. 8, pp. 645–652, 2015. View at: Publisher Site | Google Scholar
  8. C. Xin, Z. Xia, C. Jiang, M. Lin, and G. Li, “Xiaokeping mixture inhibits diabetic nephropathy in streptozotocin-induced rats through blocking TGF-β1/Smad7 signaling,” Drug Design, Development and Therapy, vol. 9, pp. 6269–6274, 2015. View at: Publisher Site | Google Scholar
  9. Chinese Pharmacopoeia Commission, Chinese Pharmacopoeia, The Medicine Science and Technology Press of China, Beijing, China, 2015.
  10. W. P. Jiang, C. W. Xin, M. H. Yang, X. L. Yang, G. H. Li, and Z. N. Xia, “Research of xiaokeping mixture on blood lipid and ETS-1 of STZ-induced diabetic nephropathy rats,” Chinese Archives of Traditional Chinese Medicine, vol. 35, no. 3, pp. 706–708, 2017. View at: Google Scholar
  11. Y. Wu, Y. Hu, Z. Haiyan, W. YunLin, K. Xincong, and L. Dongbo, “Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress,” Biomedicine & Pharmacotherapy, vol. 105, pp. 407–412, 2018. View at: Publisher Site | Google Scholar
  12. M. P. Lu, C. W. Xin, B. H. Yang, X. L. Yang, and G. H. Li, “Research of xiaokeping mixture on kidney function and miR-192 of STZ-induced diabetic nephropathy,” Chinese Archives of Traditional Chinese Medicine, vol. 35, no. 5, pp. 1285–1288, 2017. View at: Google Scholar
  13. X. X. Yuan, Z. Q. Gong, B. Y. Wang et al., “Astragaloside inhibits hepatic fibrosis by modulation of TGF-β1/Smad Signaling pathway,” Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 3231647, 13 pages, 2018. View at: Publisher Site | Google Scholar
  14. H. D. Cai, S. L. Su, Y. H. Li et al., “Protective effects of Salvia miltiorrhiza on adenine-induced chronic renal failure by regulating the metabolic profiling and modulating the NADPH oxidase/ROS/ERK and TGF-β/Smad signaling pathways,” Journal of Ethnopharmacology, vol. 212, pp. 153–165, 2017. View at: Publisher Site | Google Scholar
  15. Y. Yang, H. Nian, X. Tang, X. Wang, and R. Liu, “Effects of the combined herba epimedii and Fructus ligustri lucidi on bone turnover and TGF-β1/Smads pathway in GIOP rats,” Journal of Ethnopharmacology, vol. 201, pp. 91–99, 2017. View at: Publisher Site | Google Scholar
  16. J. Lv, Z. Wang, Y. Wang et al., “Renoprotective effect of the Shen-Yan-Fang-shuai formula by inhibiting TNF-α/NF-κB Signaling pathway in diabetic rats,” Journal of Diabetes Research, vol. 2017, Article ID 4319057, 11 pages, 2017. View at: Publisher Site | Google Scholar
  17. A. Kibel, K. Selthofer-Relatic, I. Drenjancevic et al., “Coronary microvascular dysfunction in diabetes mellitus,” Journal of International Medical Research, vol. 45, no. 6, pp. 1901–1929, 2017. View at: Publisher Site | Google Scholar
  18. T. A. Lutu and S. C. Woods, “Overview of animal models of obesity,” Current Protocols in Pharmacology, vol. 58, no. 1, pp. 5.61.1–5.61.18, 2012. View at: Publisher Site | Google Scholar
  19. M. Yang, L. Song, C. Strange, X. Dong, and H. Wang, “Therapeutic effects of adipose stem cells from diabetic mice for the treatment of type 2 diabetes,” Molecular Therapy, vol. 26, no. 8, pp. 1921–1930, 2018. View at: Publisher Site | Google Scholar
  20. M. Kitada, Y. Ogura, and D. Koya, “Rodent models of diabetic nephropathy: their utility and limitations,” International Journal of Nephrology and Renovascular Disease, vol. 9, no. 9, pp. 279–290, 2016. View at: Publisher Site | Google Scholar
  21. K. F. Zar, J. Han, R. Ksouri, C. Abdelly, and H. Isoda, “Oral administration of Nitraria retusa ethanolic extract enhances hepatic lipid metabolism in db/db mice model 'BKS.Cg-Dock7(m)+/+ Lepr(db/)J' through the modulation of lipogenesis-lipolysis balance,” Food and Chemical Toxicology, vol. 72, pp. 247–256, 2014. View at: Publisher Site | Google Scholar
  22. F. Tang, Y. Hao, X. Zhang, and J. Qin, “Effect of echinacoside on kidney fibrosis by inhibition of TGF-β1/Smads signaling pathway in the db/db mice model of diabetic nephropathy,” Drug Design, Development and Therapy, vol. 11, pp. 2813–2826, 2017. View at: Publisher Site | Google Scholar
  23. W. Xie and L. Du, “Diabetes is an inflammatory disease: evidence from traditional Chinese medicines,” Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 289–301, 2011. View at: Publisher Site | Google Scholar
  24. L. S. He, H. Wang, C. J. Gu, X. H. He, L. H. Zhao, and X. L. Tong, “Administration of traditional Chinese blood circulation activating drugs for microvascular complications in patients with type 2 diabetes mellitus,” Journal of Diabetes Research, vol. 2016, Article ID 1081657, 9 pages, 2016. View at: Publisher Site | Google Scholar
  25. H. Sabbineni, A. Verma, and P. R. Somanath, “Isoform-specific effects of transforming growth factor β on endothelial-to-mesenchymal transition,” Journal of Cellular Physiology, vol. 233, no. 11, pp. 8418–8428, 2018. View at: Publisher Site | Google Scholar
  26. K. Verschueren, J. E. Remacle, C. Collart et al., “SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5-CACCT Sequences in candidate target genes,” Journal of Biological Chemistry, vol. 274, no. 29, pp. 20489–20498, 1999. View at: Publisher Site | Google Scholar
  27. A. Miyoshi, Y. Kitajima, K. Sumi et al., “Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells,” British Journal of Cancer, vol. 90, no. 6, pp. 1265–1273, 2004. View at: Publisher Site | Google Scholar
  28. L.-F. Zeng, Y. Xiao, and L. Sun, “A glimpse of the mechanisms related to renal fibrosis in diabetic nephropathy,” Advances in Experimental Medicine and Biology, vol. 1165, pp. 49–79, 2019. View at: Publisher Site | Google Scholar
  29. L. Aresu, M. P. Rastaldi, P. Pregel et al., “Dog as model for down-expression of E-cadherin and β-catenin in tubular epithelial cells in renal fibrosis,” Virchows Archiv, vol. 453, no. 6, pp. 617–625, 2008. View at: Publisher Site | Google Scholar
  30. R. R. Allen, L. Qi, and P. J. Higgins, “Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes,” Journal of Cellular Physiology, vol. 203, no. 1, pp. 156–165, 2005. View at: Publisher Site | Google Scholar
  31. J. Comijn, G. Berx, P. Vermassen et al., “The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion,” Molecular Cell, vol. 7, no. 6, pp. 1267–1278, 2001. View at: Publisher Site | Google Scholar
  32. B. Wang, M. Herman-Edelstein, P. Koh et al., “E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-,” Diabetes, vol. 59, no. 7, pp. 1794–1802, 2010. View at: Publisher Site | Google Scholar
  33. D. Ko and S. kim, “Cooperation between ZEB2 and Sp1 promotes cancer cell survival and angiogenesis during metastasis through induction of survivin and VEGF,” Oncotarget, vol. 9, no. 1, pp. 726–742, 2018. View at: Publisher Site | Google Scholar
  34. Z. Yang, B. Sun, Y. Li et al., “ZEB2 promotes vasculogenic mimicry by TGF-β1 induced epithelial-to-mesenchymal transition in hepatocellular carcinoma,” Experimental and Molecular Pathology, vol. 98, no. 3, pp. 352–359, 2015. View at: Publisher Site | Google Scholar
  35. G. Bassez, O. J. A. Camand, V. Cacheux et al., “Pleiotropic and diverse expression of ZFHX1B gene transcripts during mouse and human development supports the various clinical manifestations of the “Mowat-Wilson” syndrome,” Neurobiology of Disease, vol. 15, no. 2, pp. 240–250, 2004. View at: Publisher Site | Google Scholar
  36. M. Kato, J. Zhang, M. Wang et al., “MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors,” Proceedings of the National Academy of Sciences, vol. 104, no. 9, pp. 3432–3437, 2007. View at: Publisher Site | Google Scholar

Copyright © 2019 Bo Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

533 Views | 266 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.